CHLR1/DDX11 depletion was also found to sensitize cancer cells to poly ADP-ribose polymerase (PARP) inhibitors and platinum-based chemotherapy and enhances the sensitivity to chemotherapy of cells with BRCA1 or BRCA2 mutations [130]. The gene discussed is DDX11; the disease is cancer.